Development of Mycobacterium avium Complex Lung Disease in Patients With Lung Cancer on Immune Checkpoint Inhibitors

Immunotherapy with immune checkpoint inhibitors (ICIs), while ameliorating lung cancer, can cause infectious diseases, including tuberculosis, in addition to immune-related noninfectious complications. In the clinical setting, the efficacy of ICIs to treat mycobacterial infection remains controversi...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujita, Kohei, Yamamoto, Yuki, Kanai, Osamu, Okamura, Misato, Nakatani, Koichi, Mio, Tadashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066797/
https://www.ncbi.nlm.nih.gov/pubmed/32190712
http://dx.doi.org/10.1093/ofid/ofaa067
_version_ 1783505313397211136
author Fujita, Kohei
Yamamoto, Yuki
Kanai, Osamu
Okamura, Misato
Nakatani, Koichi
Mio, Tadashi
author_facet Fujita, Kohei
Yamamoto, Yuki
Kanai, Osamu
Okamura, Misato
Nakatani, Koichi
Mio, Tadashi
author_sort Fujita, Kohei
collection PubMed
description Immunotherapy with immune checkpoint inhibitors (ICIs), while ameliorating lung cancer, can cause infectious diseases, including tuberculosis, in addition to immune-related noninfectious complications. In the clinical setting, the efficacy of ICIs to treat mycobacterial infection remains controversial. We report 3 cases of acute Mycobacterium avium complex lung disease during immunotherapy with ICIs.
format Online
Article
Text
id pubmed-7066797
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-70667972020-03-18 Development of Mycobacterium avium Complex Lung Disease in Patients With Lung Cancer on Immune Checkpoint Inhibitors Fujita, Kohei Yamamoto, Yuki Kanai, Osamu Okamura, Misato Nakatani, Koichi Mio, Tadashi Open Forum Infect Dis Brief Report Immunotherapy with immune checkpoint inhibitors (ICIs), while ameliorating lung cancer, can cause infectious diseases, including tuberculosis, in addition to immune-related noninfectious complications. In the clinical setting, the efficacy of ICIs to treat mycobacterial infection remains controversial. We report 3 cases of acute Mycobacterium avium complex lung disease during immunotherapy with ICIs. Oxford University Press 2020-03-07 /pmc/articles/PMC7066797/ /pubmed/32190712 http://dx.doi.org/10.1093/ofid/ofaa067 Text en © The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Brief Report
Fujita, Kohei
Yamamoto, Yuki
Kanai, Osamu
Okamura, Misato
Nakatani, Koichi
Mio, Tadashi
Development of Mycobacterium avium Complex Lung Disease in Patients With Lung Cancer on Immune Checkpoint Inhibitors
title Development of Mycobacterium avium Complex Lung Disease in Patients With Lung Cancer on Immune Checkpoint Inhibitors
title_full Development of Mycobacterium avium Complex Lung Disease in Patients With Lung Cancer on Immune Checkpoint Inhibitors
title_fullStr Development of Mycobacterium avium Complex Lung Disease in Patients With Lung Cancer on Immune Checkpoint Inhibitors
title_full_unstemmed Development of Mycobacterium avium Complex Lung Disease in Patients With Lung Cancer on Immune Checkpoint Inhibitors
title_short Development of Mycobacterium avium Complex Lung Disease in Patients With Lung Cancer on Immune Checkpoint Inhibitors
title_sort development of mycobacterium avium complex lung disease in patients with lung cancer on immune checkpoint inhibitors
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066797/
https://www.ncbi.nlm.nih.gov/pubmed/32190712
http://dx.doi.org/10.1093/ofid/ofaa067
work_keys_str_mv AT fujitakohei developmentofmycobacteriumaviumcomplexlungdiseaseinpatientswithlungcanceronimmunecheckpointinhibitors
AT yamamotoyuki developmentofmycobacteriumaviumcomplexlungdiseaseinpatientswithlungcanceronimmunecheckpointinhibitors
AT kanaiosamu developmentofmycobacteriumaviumcomplexlungdiseaseinpatientswithlungcanceronimmunecheckpointinhibitors
AT okamuramisato developmentofmycobacteriumaviumcomplexlungdiseaseinpatientswithlungcanceronimmunecheckpointinhibitors
AT nakatanikoichi developmentofmycobacteriumaviumcomplexlungdiseaseinpatientswithlungcanceronimmunecheckpointinhibitors
AT miotadashi developmentofmycobacteriumaviumcomplexlungdiseaseinpatientswithlungcanceronimmunecheckpointinhibitors

Ejemplares similares